Antibiotic Disincentives? Medicare Decisions Underscore Limits Of Add-On Payments
Executive Summary
CMS disappointed stakeholders looking for antibiotic payment incentives from Medicare with two recent decisions. One was to withhold new technology add-on payments from Dalvance and the other to allow existing NTAP benefits for Dificid to expire.